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Apramycin represents a subclass of aminoglycoside antibiotics that has been shown to evade almost all 
mechanisms of clinically relevant aminoglycoside resistance. Model-informed drug development may facilitate its 
transition from preclinical to clinical phase. This study explored the potential of pharmacokinetic/pharmacodynamic 
(PK/PD) modeling to maximize the use of in vitro time-kill and in vivo preclinical data for prediction of a human 
efficacious dose (HED) for apramycin. PK model parameters of apramycin from four different species (mouse, rat, 
guinea pig, and dog) were allometrically scaled to humans. A semimechanistic PK/PD model was developed from 
the rich in vitro data on four Escherichia coli strains and subsequently the sparse in vivo efficacy data on the same 
strains were integrated. An efficacious human dose was predicted from the PK/PD model and compared with the 
classical PK/PD index methodology and the aminoglycoside dose similarity. One-compartment models described 
the PK data and human values for clearance and volume of distribution were predicted to 7.07 L/hour and 26.8 L, 
respectively. The required fAUC/MIC (area under the unbound drug concentration-time curve over MIC ratio) targets 
for stasis and 1-log kill in the thigh model were 34.5 and 76.2, respectively. The developed PK/PD model predicted 
the efficacy data well with strain-specific differences in susceptibility, maximum bacterial load, and resistance 
development. All three dose prediction approaches supported an apramycin daily dose of 30 mg/kg for a typical 
adult patient. The results indicate that the mechanistic PK/PD modeling approach can be suitable for HED prediction 
and serves to efficiently integrate all available efficacy data with potential to improve predictive capacity.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 The human efficacious dose (HED) is predicted based on 
preclinical data to support clinical drug development. The 
pharmacokinetic/pharmacodynamic (PK/PD) relationships 
of antibiotics are typically defined using the PK/PD index 
methodology.
WHAT QUESTION DID THIS STUDY ADDRESS?
 In this study, PK and efficacy data from in vitro and in vivo 
studies in preclinical drug development were combined for 
translational PK and PK/PD modeling to support HED pre-
diction. The predicted dose was compared with the dose sug-
gested from the classical PK/PD index methodology.
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 The results indicate that the PK/PD modeling approach can 
be suitable for HED prediction. Furthermore, the modeling al-
lowed for integration of all available data mechanistically with 
predictive capacity not possible to achieve using the classical 
methodology.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 This work has shown how PK/PD modeling can maximize 
the information gain from preclinical antibiotic studies on ef-
ficacy. The potential for model-informed drug development in 
the translation of antibiotics is demonstrated.
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Aminoglycosides are potent broad-spectrum antibiotics that 
bind to bacterial ribosomes to inhibit protein biosynthesis.1,2 
Apramycin is a monosubstituted deoxystreptamine and this 
uniquely distinctive chemical structure from other aminoglyco-
sides minimizes the cross-resistance to apramycin.3–6 In addition, 
apramycin has also been demonstrated to have a low potential for 
toxicity.7,8 These properties make apramycin an attractive candi-
date for development into a new clinical therapy.
The human efficacious dose (HED) is predicted based on pre-
clinical data to support clinical development. The drug exposure 
related to HED, and the drug exposure related the no-observed-ad-
verse-effect level, define the anticipated therapeutic window. 
Hence, human dose estimation is dependent on reliable prediction 
of human pharmacokinetics (PK) and pharmacodynamics (PD).9 
To this end, predictions of human PK from PK parameters in pre-
clinical species are made (e.g., based on allometric scaling).10–12 
This is the choice for drugs eliminated by the kidney because there 
is no reliable in vitro methods for predicting renal clearance.13,14
In the past decades, the PK/PD relationships of antibiotics 
have been described by evaluating the correlation of PK/PD 
indices (i.e., fAUC/MIC, fCmax/MIC, and fT>MIC), which 
are summary measures of drug exposure in relation to the min-
imum inhibitory concentration (MIC) of the drug, to an out-
come variable, such as 24-hour response in an animal infection 
model.15–18 From the index with the best correlation, a PK/PD 
target is derived. With a population PK model for humans and 
Monte–Carlo simulations, the probability of target attainment 
(PTA) in the virtual population, given the derived PK/PD tar-
gets, are evaluated for different dosing regimens.15 These PK/
PD indices are, however, simplifications of the PK/PD relation-
ships neglecting the time-course of PK and PD. In addition, 
given the reliance on MIC, these PK/PD indices also suffer from 
the drawbacks of MICs (i.e., these are crude threshold values ne-
glecting measurement error and the dynamic nature of bacterial 
growth and susceptibility).19,20
In vitro time course of bacterial growth and killing are used for 
development of semimechanistic PK/PD models.15,21 In conjunc-
tion with the predicted human PK profiles, such PK/PD models 
have been used to predict alternative human dosages of available 
drugs.9,22,23 In this study, PK and efficacy data from in vitro and in 
vivo studies in preclinical development were combined for trans-
lational PK and PK/PD modeling. The predicted dose from the 
modeling approach was compared with the doses predicted using 
the classical PK/PD index methodology based on PTA for stasis 




Pharmacokinetic studies. Animals (see Supplementary Table S1 for 
details) were housed under standard conditions (21–23°C, reversed 12-
hour light/dark cycle, and relative humidity 45–65%) with unlimited 
access to food and water. The experimental procedures were performed 
in accordance with the guidelines of the European Community and local 
laws and policies (Directive 2010/63/EU), and all of the procedures 
were approved by the Food and Veterinary Service, Riga, Latvia, and by 
the National Committee of Animal Ethics, Ministry of Environment 
and Food of Denmark. Concentrations of apramycin were measured in 
plasma samples from mice, rats, guinea pigs, and dogs following either 
s.c. or i.v. administration. Briefly, NMRI mice, Sprague-Dawley rats, and 
Hartley guinea pigs were given s.c. doses of apramycin, whereas beagle 
dogs were given i.v. doses of apramycin either as a bolus dose or 25-min-
ute infusion. Plasma samples were collected at predetermined time points 
(Supplementary Table S1).
Plasma sample analyses were performed using a quantitative ul-
traperformance liquid chromatography-tandem mass spectrometry 
(UPLC-MS/MS) method. Briefly, a sample volume of 10 μL was trans-
ferred into a plastic tube and mixed with 20  μL trichloroacetic acid 
(10% aqueous solution) to precipitate proteins. The mixture was diluted 
with 470 μL of mobile phase A (0.01% of heptafluorobutyric acid and 
0.01% of propionic acid aqueous solution) and centrifuged at 20000x g  
for 10  minutes. Supernatant was subjected to UPLC-MS/MS analysis 
on an UPLC system Acquity H-class (Waters) connected with triple 
quadrupole mass spectrometer Xevo TQ-S (Waters). UPLC conditions: 
column-Acquity BEH C18 (2.1  ×  50  mm, 1.7  μm); mobile phase A: 
0.01% HFBA solution in 0.01% propionic acid aqueous solution, B: 
0.01% HFBA solution in 0.01% propionic acid solution in acetonitrile; 
gradient initial 17%B, 0.5 minutes 17%B, 1.6 minutes 80%B, 3 minutes 
80%B, 3.5  minutes 17%B, 5  minutes 17%B; flow 0.4  mL/minute; col-
umn temperature 40°C; and injection volume 1 μL. MS conditions: ion-
ization electrospray ionization positive mode; capillary voltage 1.0  kV; 
electrospray ionization source temperature 120°C; desolvation gas (N2) 
flow 800 L/hour; and desolvation temperature 600°C. Multiple reaction 
monitoring parameters were as follows: m/z 540.2 → m/z 378.0 at cone 
voltage 80  V and collision energy 15  eV. The UPLC-MS/MS method 
quantified apramycin plasma concentrations in the range 1.28–1,315 μg/
mL (mouse), 0.80–615 μg/mL (rat), 2.53–615 μg/mL (guinea pig), and 
0.84 to 68 μg/mL (dog).
Time-kill experiments. Time-kill experiments were performed on four 
Escherichia coli strains (ATCC 25922, a reference strain for antibiotic 
susceptibility testing; ATCC 700336, an SXT-resistant urinary tract 
infection isolate; EN335, a multidrug-resistant ESBL-positive clinical 
isolate; and EN591, a multidrug-resistant rmtB isolate) with MICs 
ranging from 4 to 8  mg/L. Briefly, overnight cultures of each strain 
were diluted 100-fold into 2 mL pre-warmed Mueller Hinton II broth, 
grown 1.5 hours to logarithmic phase (OD600 0.1–0.3), then aliquots 
of ~ 106 bacteria were inoculated into polypropylene tubes containing 
2 mL pre-warmed MHII medium pH 7.3. Apramycin was added to the 
tubes to achieve the intended concentration range (Supplementary 
Table S2). The tubes were incubated at 37°C and samples were taken 
for viable counts at 0, 1, 2, 4, 6, 8, 10, 24, and 28 hours. Appropriate 
dilutions of each sample were made in 0.9% NaCl and spread on 
MHII agar plates using glass beads (5 beads/plate, 6  mm diameter, 
Hecht 1401/6). After sampling, agar plates were incubated at 37°C for 
18–24 hours before the number of colony-forming units (CFUs) was 
counted manually. The limit of detection was 10 CFU/mL.
In vivo efficacy studies in mice. The protocols of the studies were ap-
proved by the local animal ethics committees (SSI, Denmark). Brief ly, 
female NMRI mice (5–6 weeks old, 26–30 g, N = 6) were rendered 
neutropenic via i.p. injection of 2 doses of cyclophosphamide on day 
4 and day 1 before infection. The animals were infected on day 0 via 
intramuscular injection of an inoculum containing 106 bacteria/mL 
in the left thigh. The same strains of E.  coli were used as in the in 
vitro experiments. The animals were treated with apramycin ranging 
from 0.39 to 2,400  mg/kg/day starting at 1  hour after inoculation. 
The daily doses were fractionated into smaller doses for s.c. admin-
istration. Animals were either euthanized at the start of treatment or 
at the study end point after treatment initiation. Thighs were asep-
tically removed from the animals, homogenized, diluted, and plated 
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for incubation. Bacterial counting was performed after 18–22 hours 
of incubation at 35°C in ambient air.
PK/PD model development
PK modeling and prediction of human PK parameters. The PK pa-
rameters were estimated for each of the four species separately. Because 
only s.c. data were available for mice, rats, and guinea pigs, bioavailability 
(F) was set to 1 for estimation of the other PK parameters. Clearance 
(CL) and volume of distribution (V) of each animal were parameterized 
during the estimation, as shown in Eqs. 1 and 2:
where CLi and Vi are the individual animal parameters and WT (kg) is 
the animal body weight. CL and V are the typical parameters of a human 
adult with a body weight of 70 kg.
One-compartment and two-compartment models with first-order 
absorption and linear elimination or saturable (nonlinear) elimination 
were evaluated. The observed dose-dependency in absorption in the 
mouse studies was explored by scaling the absorption rate constant (ka) 
to the 30 mg/kg dose, as shown in Eq. 3, where ka30 is the ka at 30 mg/kg 
and the power parameter pow was estimated.
The PK parameters estimated from the animal species were used for al-
lometric scaling to predict human CL and V of apramycin. Because human 
clearances are generally well-predicted using simple allometry for renally 
cleared drugs,24 simple allometry was used as shown in Eq. 4, where CLu 
is the clearance based on unbound drug, a is the allometric coefficient, b is 
the scaling exponent, and WT is the body weight.10 CL and V parameters 
were corrected with the unbound fractions ( fus) in each animal species. 
The fu values for mouse, rat, guinea pig, dog, and human had been deter-
mined to 0.58, 0.67, 0.59, 0.58, and 0.62, respectively (in-house data).
PK/PD modeling. A PK/PD model was developed by first utilizing the 
in vitro time-kill data. Initially, strain-dependent models were devel-
oped and then all time-kill data were combined for simultaneous analy-
sis. The model was adapted from an earlier model applied to gentamicin, 
another aminoglycoside antibiotic, and details of the equations used in 
the model can be found in an earlier publication.25 To describe the re-
growth of bacteria as observed in the time-kill data, adaptive resistance 
was included in the model.26–29 The natural bacteria kill rate constant 
(kdeath) was fixed to 0.179 hour
–1 as in previous publications.30
The model developed from the in vitro time-kill data was then used 
to analyze the in vivo efficacy data by first fitting the model to the in 
vivo growth control data to estimate the in vivo growth rate constant and 
delay. The kgrowth for in vitro and in vivo growth was parameterized, as 
shown in Eqs. 5 and 6:
where kg _vitro, kg _vivo, T, Tdelay, and β represent the growth rate constant 
in vitro, the growth rate constant in vivo, the time since bacteria in-
jection, the median duration of delay in growth, and the sigmoidicity 
factor, respectively. In the model, β was fixed to 5 to describe a gradual 
increase in growth of bacteria in vivo. To stabilize the model, system 
growth capacity in vivo (Bmax) for each strain was fixed to the mean 
value observed from the growth control data at the study end point. 
Thereafter, in vivo efficacy data from the different dosing regimens 
were added to the model for analysis. Plasma concentrations of apramy-
cin as predicted by the PK model for mice were converted to unbound 
concentrations to drive in vivo bacterial killing in the PK/PD model.
PK/PD indices
Data from 24-hour dose fractionation studies in the murine thigh infec-
tion model were available for the same four E. coli strains as those studied 
in vitro. The three PK/PD indices, fAUC/MIC, f T>MIC, and fCmax/
MIC, were computed based on the PK parameters estimated for mice and 
correlated to the response at 24 hours after the start of treatment. The 
PK/PD targets of stasis and 1-log reduction were determined by compos-
ite regression analysis.
Human efficacious dose prediction
Given the human dosing recommendations for aminoglycosides in the 
literature,31 only once-daily regimens were considered. For the PK/PD 
model-based approach, suitable doses were predicted for E. coli infections 
using the PK/PD model developed by finding the dose that predicts sta-
sis. Unbound plasma concentrations in a typical patient with a creatinine 
clearance (CrCL) of 80 mL/minute (typical value of critically ill patients), 
as predicted from the allometrically scaled PK parameters, were driving 
the PK/PD model. For the PK/PD index approach, unbound concentra-
tion-time profiles of 1,000 virtual patients with a CrCL of 80 mL/minute 
were simulated from the population PK model of gentamicin32 to perform 
the PTA analysis. For aminoglycoside similarity, clinically validated doses 
of aminoglycosides were scaled by the expected differences in their MICs, 
based on the ratios between the MIC90 of apramycin for Enterobacteriaceae 
(8 mg/L) and the clinical breakpoint/MIC values of gentamicin, plazomi-
cin,6 and amikacin according to EUCAST (www.eucast.org).
Data analysis and software
Model development was performed using the nonlinear mixed-ef-
fects modeling software NONMEM version 7.4 (ICON Development 
Solutions, San Antonio, TX), with Perl-speaks-NONMEM,33 and the 
Laplacian conditional estimation method with interaction. R (version 
3.5; R Foundation for Statistical Computing, Vienna, Austria) with the 
Xpose package was used for data management and graphical evaluation.34 
The data were log-transformed for modeling (i.e., transform-both-sides-
approach). Data below the lower limit of detection were handled using 
the likelihood-based M3 method.35 Interindividual variability was not 
estimated.
The likelihood ratio test was used to evaluate statistical significance 
for inclusion of additional parameters, where the objective function value 
(OFV) is assumed to be χ2 distributed. For nested models with one pa-
rameter difference, a change in OFV (dOFV) of ≥ 3.84 was considered 
as a statistical difference at the 5% significance level (i.e., P  <  0.05, for 
1 degree of freedom). For residual unexplained variability, proportional 
error models, as approximated by log-transformed additive error mod-
els, were used. Model development was guided by scientific plausibility, 
dOFV, parameter precision, and goodness-of-fit plots, including the simu-
lation-based visual predictive checks.
RESULTS
Pharmacokinetics of apramycin in preclinical species
The PK data from mice, rats, and guinea pigs were well-described 
by one-compartment models (Table  1). A dose-dependent ka 
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was significant for mice (dOFV = −49.6). The PK of apramy-
cin in these preclinical species were not significantly different 
to gentamicin (in-house data). For dogs, the data supported a 
two-compartment model. However, because the clearance and 
total volume of distributions were comparable for one-compart-
ment and two-compartment models, the PK parameters from the 
one-compartment model were used in the allometric scaling for 
consistency with the other species.
Prediction of human pharmacokinetic parameters
The CL and V values predicted by allometric scaling for a 70 kg 
healthy human based on total drug concentrations were 7.07 L/
hour and 26.8 L, respectively (Supplementary Figure S1). For a 
typical patient with CrCL of 80 mL/minute, CL is expected to be 
4.71 L/hour, assuming elimination can be scaled proportionally 
to CrCL. Based on the allometrically scaled PK parameters, the 
total concentrations of apramycin in humans were predicted to 
be ~ 75 mg/L at 0.5 hour after a 30 mg/kg i.v. dose infused over 
0.5 hour. The predicted concentrations of apramycin were similar 
to those predicted using the gentamicin PK model reported in the 
literature32 (Supplementary Figure S2).
PK/PD modeling with in vitro and in vivo efficacy data
The general structure of the PK/PD model is illustrated in 
Figure  1. Some parameter differences among the four strains 
were noted in the final PK/PD model (Table 2). For the mul-
tidrug-resistant strain EN591, the observed range of concen-
trations was relatively narrow in relation to its MIC and a 
maximum effect (Emax) model was not supported. Therefore, 
a linear relationship was applied and it was estimated to have 
the same slope (Emax/half-maximal effective concentration 
(EC50)) as for ATCC 25922. EN335 and ATCC 700336 shared 
the same Emax (slope  ×  EC50), estimated to 66.3  hour
–1. The 
growth rate constant was not significantly different between 
the strains. The delay of drug action in vivo was described by 
an effect compartment, and the EC50 was about 5% of what was 
estimated from the time-kill data. The visual predictive checks 
demonstrate a good fit to the time-kill and in vivo efficacy data 
(Figure 2).
Predicted bacterial killing curves in mice
The 24-hour bacterial killing following treatment of apramycin 
at 100 mg/kg q6h in mice was predicted from the developed PK/
PD model (Figure 3a). The prediction showed a rapid killing at the 
start of the treatment, followed by a gradual regrowth of bacteria 
and eventually stasis at 24 hours. The 24-hour results are consistent 
with the observed data for which this regimen resulted in stasis at 
24 hours for all 4 E. coli strains.
PK/PD targets from in vivo studies
When the in vivo efficacy data were plotted against the PK/PD in-
dices, it was apparent that although f T> MIC appeared to be a good 
predictor of 24-hour response in the thigh infection model for apra-
mycin, fAUC/MIC also showed a good correlation (Figure 4). The 
correlation between efficacy and fAUC/MIC increased (r2 = 0.56 
vs. 0.74) when only dosing regimens up to q6h were included. The 
PK/PD targets of stasis and 1-log reduction were determined to be 
34.5 for stasis and 76.2 for 1-log kill (Figure 4).
Prediction of human efficacious dose
Dose prediction using the PK/PD model. The PK model 
of apramycin with predicted human PK parameters from 
allometric scaling was used to drive killing in the final PK/
PD model. The dose that typically resulted in a bacterial count 
of stasis at 24 hours for the 4 strains was 30 mg/kg. This dose 
resulted in a similar time-kill profile as 100 mg/kg q6h in mice 
(Figure  3b). Consequently, based on this model, a 30  mg/kg 
q24h dose in humans is expected to be as efficient as a 100 mg/
kg q6h regimen in mice at 24 hours.
PTA based on the PK/PD stasis target. Based on the PTA analysis, 
to reach a fAUC/MIC target of 30 in >  90% of the patients 
infected with bacteria with an MIC of 8 mg/L, apramycin doses 
of 30 mg/kg once daily were predicted to be sufficient (Figure 5). 
A high gentamicin dose of 7 mg/kg was predicted to cover bacteria 
with MICs  ≤  2  mg/L and ≤  0.5  mg/L in 95% of the patient 
population based on targets of 30 and 80, respectively. Apramycin 
concentrations after a 30  mg/kg q24h dose are predicted to 
Table 1 Parameter estimates of the final PK models in the preclinical species and the resulting human parameters 
predicted from allometric scaling
Unit Description Mouse Rat GP Dog Human
fu — Fraction unbound 0.58 0.67 0.59 0.58 0.62
CL/F L/hour/70 kg Clearance 8.49 5.97 5.34 8.05 11.4
V/F L/70 kg Volume of distribution 6.55 8.78 11.0 17.8 43.3
ka hour
−1 Absorption rate constant — 1.2 0.922 — —
ka30
a hour−1 Absorption rate constant 
at 30 mg/kg
2.17 — — —
pow — Scaling exponent for 
dose-dependent Ka
-0.160 — — — —
ERR % Residual error 49 31 25 19.3 —
GP, guinea pig.
aFor mouse, the absorption rate at any given dose (ka) is dose-dependent by scaling ka30 with pow as shown in Eq. 3 (see section PK/PD model development).
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be above 2 and 8  mg/L (MIC90 for E.  coli) for ~  20–24 and 
8–24 hours, respectively, for 90% of patients in a population with 
a CrCL of 80 mL/minute.
Aminoglycoside similarity. Considering the clinical breakpoints 
of aminoglycosides, a four times higher daily dose of apramycin 
compared with the high dose gentamicin (7 mg/kg) would result 
in ~ 30 mg/kg. Assuming the same PK for amikacin, and given 
the same rationale and a clinical breakpoint of 8 mg/L, a clinical 
daily dose of 30 mg/kg amikacin would also scale to a 30 mg/kg 
dose of apramycin. Similarly, the 15  mg/kg dose of plazomicin, 
with an expected breakpoint of 4  mg/L,6 would also scale to a 
30 mg/kg dose of apramycin.
DISCUSSION
To determine the dose levels to be investigated in first-in-human 
trials, the prediction of HED from preclinical data is key. The 
traditional approaches for HED prediction include the classical 
PK/PD index approach and a PK-guided approach.22,23,36 Here, 
a PK/PD model characterizing the time-courses of antibiotic-in-
duced bacterial killing, was developed based on in vitro time-kill 
data, in combination with in vivo mouse infection data, to predict 
the human dose. This approach has the potential to advance the 
transition of information from preclinical to clinical studies in an-
tibiotic drug development. Given the ability of semimechanistic 
PK/PD models to bridge between different types of preclinical 
experiments,30,37–40 such models may provide valuable assistance 
in choosing a reasonable HED. Furthermore, the model-based ap-
proach applied here diminishes the need to classify the PK/PD re-
lationship into one of the three PK/PD indices. As illustrated, the 
data do not always discriminate well between the PK/PD indices, 
implying that antibiotics may not fit into being either “time-de-
pendent” or “concentration-dependent.” Furthermore, resistant 
development is ignored in the classical PK/PD index approach.
In the present study, human PK was predicted by analyzing the 
PK data collected from four preclinical species. Multicompartment 
models have previously been reported for aminoglycosides in pa-
tients.32,41 However, our data only supported one-compartment 
models for the preclinical species. Studies with i.v. administration 
and more frequent sampling for a longer duration of time would 
be needed to support more complex models. Nevertheless, the pa-
rameters and concentration-time profiles predicted from allome-
tric scaling, highlighted the similarity of PK between apramycin 
and gentamicin. This suggests that the PK of apramycin in patients 
is also likely to be similar to the PK of gentamicin, and a first-in-
human trial is currently in progress (ClinicalTrials.gov Identifier: 
NCT04105205).
The preclinical efficacy data were unique in the way that the 
same four strains were studied both in vitro and in vivo. The data 
were analyzed simultaneously to estimate PD parameters for apra-
mycin. Regrowth at 24  hours was apparent for all strains in the 
time-kill experiments and explained by a function of aminoglyco-
side-induced adaptive resistance in the PK/PD model.25 Adaptive 
resistance is known as a nonmutational phenotypic resistance, or 
antibiotic-induced tolerance, characterized by its transient na-
ture.29,42 In the present study, a simpler empirical model with only 
bacterial growth and killing was not able to adequately describe the 
data and the exposure-response relationship. In the model, the dif-
ferences in the time-kill curves between strains could be explained 
by the differences in maximum growing capacity, drug susceptibil-
ity, and rate of resistance development. The different drug effects 
Figure 1 Schematic diagram of the pharmacokinetic/pharmacodynamic (PK/PD) model. AR, adaptive resistance; B1, susceptible bacteria; B2, 
resting bacteria; Bmax, maximum limit of number of bacteria in the system; C, drug concentrations; Emax, maximum effect; kon, rate constant 
for onset of adaptive resistance; kons, strain specific kon; MIC, minimum inhibitory concentration.
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observed in vivo was described by a delayed drug action that could 
be due to drug distribution from plasma to the site of action and an 
increase in drug potency, as suggested by the lower EC50 parameter. 
The higher potency in vivo could potentially indicate higher free 
drug concentrations at the target site of action than what would be 
expected from the effect compartment model, or that the environ-
ment in the mouse thigh increases the susceptibility of the bacteria 
compared with in vitro conditions.
In the dose fractionation studies, apramycin showed lower 
CFU reduction following q12h and q24h dosing compared with 
the same total dose fractionated to more frequent dosing. The 
USCAST evaluation on aminoglycosides36 was based on genta-
micin, tobramycin, and amikacin with dosing intervals of 6 hours 
and shorter, because schedules of q12h or q24h were not deemed 
suitable for determining PK/PD index correlations of aminogly-
cosides given the short half-lives in relation to the dosing interval. 
Table 2 Parameter estimates and RSEs of the final PK/PD model




−1 Bacteria growth rate constant —in vitro All 2.16 3.5
Bmax Log CFU/mL Maximum bacterial count limit —in vitro ATCC 25922
a 9.38 3.5
ATCC 25922b 8.47 2.1
EN335 9.47 2
EN591 9.43 1.4
ATCC 700336 9.48 1
Maximum bacterial count limit —in vivo ATCC 25922 8.97 Fix
EN335 8.59 Fix
EN591 7.76 Fix
ATCC 700336 7.56 Fix




ATCC 700336 0.796 9.4
EC50 mg/L Drug concentration needed to achieve 50% of Emax ATCC 25922 123 17.1
EN335 156 12.7
EN591 268 13.7
ATCC 700336 83.3 14.9
kon hour
−1 Rate constant for onset of adaptive resistance, scaled 
by drug concentration and MIC
All 0.555 10.5
koff hour
−1 Rate constant for reversal of adaptive resistance All 0.005 Fix
Hill — Sigmoidicity factor for adaptive resistance All 20 Fix
IC50 mg/L Fraction needed to achieve 50% of the maximum 
concentration-driven resistance






–1 Bacteria growth rate constant —in vivo All 0.944 5.1
Tdelay Hour Growth delay in vivo All 0.849 16.1
Beta (β) — Sigmoidicity factor for growth delay in vivo All 5 Fix
keff hour
–1 Rate constant for effect compartment in vivo All 0.313 24.2
ECshift — Shift factor for EC50 in vivo
c All 0.0537 6.4
ERR % Residual error—in vitro ATCC 25922a 118.3 13.5
ATCC 25922b 140.4 12.4
EN335 74.5 30.4
EN591 66.0 13.9
ATCC 700336 80.4 17.0
Residual error—in vivo All 84.9 3.6
APR, apramycin; Bmax, maximum number of bacteria in the system; CFU, colony-forming unit; EC50, half-maximal effective concentration; Emax, maximum effect; 
ERR, residual error; IC50, half-maximal inhibitory concentration; MIC, minimum inhibitory concentration; NA, not applicable.
aATCC 25922 a and b denote data from different sets of experiments. bThe slope parameter of EN335 was computed as: SlopeEN335 = SlopeEN1085 × EC50_EN1085/
EC50_EN335. 
cEC50 in vivo was parameterized as a shift from EC50 in vitro: EC50_vivo = EC50_vitro × ECshift.
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Figure 2 Model evaluation of the final model. Visual predictive checks are illustrated for both the (a) in vitro time-kill and (b) in vivo efficacy studies 
for the four Escherichia coli strains. The plots show the observed bacterial count data (Log CFU) of ATCC 25922, ATCC 700336, EN335 and EN591 at 
different apramycin concentrations (xMIC) for in vitro time-kill studies and different dosing intervals for in vivo efficacy studies with model predictions 
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It has previously been shown that the best correlated index shifts 
toward fAUC/MIC from fT>MIC as the half-life of the drug in-
creases.37,43 In the present study, the correlation to the fAUC/MIC 
index improved when the longer dosing intervals (q12h and q24h) 
were removed from the analysis (data not shown). Previously, 
Craig noted that fAUC/MIC was the major PK/PD index cor-
relating with efficacy for aminoglycosides when dosing regimens 
varied from 1 to 6  hours in mice.44 Indeed, a short elimination 
half-life of the antibiotic in relation to the dosing interval favors 
fT>MIC. In humans, who have longer elimination half-lives, 
fAUC/MIC is more often the better index, as suggested for ami-
noglycosides. Hence, although the R2 values for fT>MIC and 
fAUC/MIC were comparable, the latter was chosen as the most 
appropriate target for PTA simulations of human dosing. The PK/
PD targets determined in this study are comparable to those stated 
by USCAST.36 For complicated urinary tract infections, where the 
Figure 3 Model-predicted bacterial killing in vivo. Predictions are shown for AATCC 25922, ATCC 700336, EN335 and EN591 in mice (a) and 
in patients (b) following 24-hour treatment of apramycin at 100 mg/kg q6h (mice) and 30 mg/kg q24h (patients) based on the final PK/PD 
model. CFU, colony-forming unit; CrCL, creatinine clearance; PK/PD, pharmacokinetic/pharmacodynamic.
Figure 4 CFU response at 24 hours vs. PK/PD indices data in the mouse thigh infection model for ATCC 25922, ATCC 700336, EN335, 
and EN591 including dosing regimens up to every 6 hours. Baseline with no effect was set to the mean value of the observed data from the 
control groups. Maximum response was fixed to four log-kill from start of treatment. The MIC was set to 8 mg/L for EN335 and 4 mg/L for all 
other strains. CFU, colony-forming unit; Cmax, peak plasma concentration; fAUC, area under the unbound drug concentration-time curve; MIC, 
minimum inhibitory concentration.
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drug concentrates at the effect site, the stasis end point in the thigh 
model has been suggested to be an appropriate surrogate target for 
efficacy.36
The PK/PD modeling approach resulted in the same dose 
prediction as the PK/PD index approach. However, the mod-
eling approach provides more information because all data can 
be considered to further the knowledge of bacterial growth, 
the concentration-effect relationship of the antibiotic, and the 
rate and concentration-dependence of resistance development. 
Furthermore, the PK/PD model developed can be used to explore 
in vivo bacterial dynamics at various time points following different 
dosing regimens. Considering the potential differences in growth 
rates and drug susceptibility, the model can also be applied to pre-
dict bacterial dynamics of untested strains with other fitnesses and 
MICs. Given that the PD measurements in animals are terminal, in 
vivo bacterial counts after apramycin dosing were only available at 
two time points. The PK/PD model allowed the prediction of the 
time course of bacterial dynamics by integrating the sparse in vivo 
data with the richer in vitro data.
The results of the three approaches investigated in the present 
study are comparable and all support a daily dose of 30  mg/kg 
for patients with a typical CrCL of 80 mL/minute. The compa-
rability of the predictions indicates that the PK/PD modeling ap-
proach can be a suitable method for dose prediction. In addition, 
this modeling approach can serve as an efficient method to inte-
grate all available in vitro and in vivo data, both PK and efficacy, 
in a mechanistic manner to increase the predictive capacity and 
allow exploration of different scenarios. Hence, the modeling ap-
proach can maximize the information obtained from the various 
studies in a way not possible with classical methods. In particu-
lar, the modeling approach can take into account the mechanism 
of action of the drug and the emergence of resistance, and hence 
project potential impact of these factors. Therefore, it can be par-
ticularly valuable for the evaluation of combination therapies, 
where drugs with different PK properties and actions are used 
concurrently, because the classical methods are only applicable 
to monotherapy. Model-informed drug development is likely 
to play an increasingly valuable role in the development of new 
treatments.
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